ImmuCell Corporation (ICCC)
NASDAQ · Healthcare
ImmuCell Corporation Operating Income 2017–2025
ImmuCell Corporation annual/quarterly operating income history and growth rate from 2017 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- ImmuCell Corporation operating income for the quarter ending March 31, 2026 was 2.0 M, a 76.21% increase year-over-year.
- ImmuCell Corporation operating income for the twelve months ending March 31, 2026 was 3.7 M, a 206.70% decrease year-over-year.
- ImmuCell Corporation annual operating income for 2025 was 1.6 M, a 200.56% decrease from 2024.
- ImmuCell Corporation annual operating income for 2024 was -1.6 M, a 71.47% decrease from 2023.
- ImmuCell Corporation annual operating income for 2023 was -5.7 M, a 150.03% increase from 2022.
- ImmuCell Corporation annual operating income for 2022 was -2.3 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
ImmuCell Corporation Operating Income — FAQ
ImmuCell Corporation (ICCC) operating income over the last 9 years — annual and quarterly figures with year-over-year growth and charts.
What is ImmuCell Corporation's operating income?
ImmuCell Corporation (ICCC) reported operating income of $2M for fiscal 2025.
Where can I see ICCC's operating income history?
The chart and table above show ImmuCell Corporation's operating income by year and by quarter, including the growth rate.